Duplicate use of angiotesin-converting enzyme (ACE) inhibitors in a community-dwelling elderly population in Poland

A. Rajska-Neumann, K. Wieczorowska-Tobis, M. Schulz, A. Breborowicz, E. Grzeskowiak, D. G. Oreopoulos

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this paper the data on the duplicate use of ACE inhibitors among a community-dwelling elderly population are presented. Using a questionnaire, 1000 subjects were interviewed concerning the use of drugs, 654 females, mean ± SD age: 72.6 ± 6.5 years. They were divided into two groups: Group A (5%) taking at least two ACE inhibitors (n = 50) and Group B: those who used either a single ACE inhibitor or no ACE inhibitor (n = 950). In Group A, 49 individuals were taking two different ACE inhibitors concomitantly and one was using three. The most commonly used ACE inhibitor was enalapril (29 of 50 subjects). Subjects in Group A consumed significantly more drugs, both of prescription (Rx) and nonprescription (OTC), compared to those in Group B (total means: 8.4 ± 2.8 vs. 6.7 ± 3.2; p < 0.01, Rx means: 6.3 ± 2.5 vs. 5.2 ± 2.8, p < 0.05, OTC means: 2.0 ± 1.6 vs. 1.6 ± 1.5, p < 0.05). Also, they were more likely to have consulted a cardiologist (17/50 vs. 201/950, p < 0.05). The duplicate use of ACE inhibitors in 5% of a population of community-dwelling elderly patients seems to be caused by both poor doctor-doctor communication and polypharmacy. This phenomenon could possibly be dangerous especially when potential additive adverse effects are taken into account.

Original languageEnglish (US)
Pages (from-to)295-301
Number of pages7
JournalArchives of Gerontology and Geriatrics
Volume44
Issue numberSUPPL.
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Independent Living
Enzyme Inhibitors
Poland
Population
community
Group
drug
Drug Prescriptions
Polypharmacy
Enalapril
medication
Communication
questionnaire
communication
Pharmaceutical Preparations

Keywords

  • ACE inhibitors
  • Duplicate use of antihypertensive drugs
  • Inappropriateness of treatment
  • Polypharmacy

ASJC Scopus subject areas

  • Aging
  • Medicine(all)

Cite this

Rajska-Neumann, A., Wieczorowska-Tobis, K., Schulz, M., Breborowicz, A., Grzeskowiak, E., & Oreopoulos, D. G. (2007). Duplicate use of angiotesin-converting enzyme (ACE) inhibitors in a community-dwelling elderly population in Poland. Archives of Gerontology and Geriatrics, 44(SUPPL.), 295-301. https://doi.org/10.1016/j.archger.2007.01.039

Duplicate use of angiotesin-converting enzyme (ACE) inhibitors in a community-dwelling elderly population in Poland. / Rajska-Neumann, A.; Wieczorowska-Tobis, K.; Schulz, M.; Breborowicz, A.; Grzeskowiak, E.; Oreopoulos, D. G.

In: Archives of Gerontology and Geriatrics, Vol. 44, No. SUPPL., 2007, p. 295-301.

Research output: Contribution to journalArticle

Rajska-Neumann, A, Wieczorowska-Tobis, K, Schulz, M, Breborowicz, A, Grzeskowiak, E & Oreopoulos, DG 2007, 'Duplicate use of angiotesin-converting enzyme (ACE) inhibitors in a community-dwelling elderly population in Poland', Archives of Gerontology and Geriatrics, vol. 44, no. SUPPL., pp. 295-301. https://doi.org/10.1016/j.archger.2007.01.039
Rajska-Neumann, A. ; Wieczorowska-Tobis, K. ; Schulz, M. ; Breborowicz, A. ; Grzeskowiak, E. ; Oreopoulos, D. G. / Duplicate use of angiotesin-converting enzyme (ACE) inhibitors in a community-dwelling elderly population in Poland. In: Archives of Gerontology and Geriatrics. 2007 ; Vol. 44, No. SUPPL. pp. 295-301.
@article{663311cfdf1042b18cf1b5c9aaaf9a46,
title = "Duplicate use of angiotesin-converting enzyme (ACE) inhibitors in a community-dwelling elderly population in Poland",
abstract = "In this paper the data on the duplicate use of ACE inhibitors among a community-dwelling elderly population are presented. Using a questionnaire, 1000 subjects were interviewed concerning the use of drugs, 654 females, mean ± SD age: 72.6 ± 6.5 years. They were divided into two groups: Group A (5{\%}) taking at least two ACE inhibitors (n = 50) and Group B: those who used either a single ACE inhibitor or no ACE inhibitor (n = 950). In Group A, 49 individuals were taking two different ACE inhibitors concomitantly and one was using three. The most commonly used ACE inhibitor was enalapril (29 of 50 subjects). Subjects in Group A consumed significantly more drugs, both of prescription (Rx) and nonprescription (OTC), compared to those in Group B (total means: 8.4 ± 2.8 vs. 6.7 ± 3.2; p < 0.01, Rx means: 6.3 ± 2.5 vs. 5.2 ± 2.8, p < 0.05, OTC means: 2.0 ± 1.6 vs. 1.6 ± 1.5, p < 0.05). Also, they were more likely to have consulted a cardiologist (17/50 vs. 201/950, p < 0.05). The duplicate use of ACE inhibitors in 5{\%} of a population of community-dwelling elderly patients seems to be caused by both poor doctor-doctor communication and polypharmacy. This phenomenon could possibly be dangerous especially when potential additive adverse effects are taken into account.",
keywords = "ACE inhibitors, Duplicate use of antihypertensive drugs, Inappropriateness of treatment, Polypharmacy",
author = "A. Rajska-Neumann and K. Wieczorowska-Tobis and M. Schulz and A. Breborowicz and E. Grzeskowiak and Oreopoulos, {D. G.}",
year = "2007",
doi = "10.1016/j.archger.2007.01.039",
language = "English (US)",
volume = "44",
pages = "295--301",
journal = "Archives of Gerontology and Geriatrics",
issn = "0167-4943",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.",

}

TY - JOUR

T1 - Duplicate use of angiotesin-converting enzyme (ACE) inhibitors in a community-dwelling elderly population in Poland

AU - Rajska-Neumann, A.

AU - Wieczorowska-Tobis, K.

AU - Schulz, M.

AU - Breborowicz, A.

AU - Grzeskowiak, E.

AU - Oreopoulos, D. G.

PY - 2007

Y1 - 2007

N2 - In this paper the data on the duplicate use of ACE inhibitors among a community-dwelling elderly population are presented. Using a questionnaire, 1000 subjects were interviewed concerning the use of drugs, 654 females, mean ± SD age: 72.6 ± 6.5 years. They were divided into two groups: Group A (5%) taking at least two ACE inhibitors (n = 50) and Group B: those who used either a single ACE inhibitor or no ACE inhibitor (n = 950). In Group A, 49 individuals were taking two different ACE inhibitors concomitantly and one was using three. The most commonly used ACE inhibitor was enalapril (29 of 50 subjects). Subjects in Group A consumed significantly more drugs, both of prescription (Rx) and nonprescription (OTC), compared to those in Group B (total means: 8.4 ± 2.8 vs. 6.7 ± 3.2; p < 0.01, Rx means: 6.3 ± 2.5 vs. 5.2 ± 2.8, p < 0.05, OTC means: 2.0 ± 1.6 vs. 1.6 ± 1.5, p < 0.05). Also, they were more likely to have consulted a cardiologist (17/50 vs. 201/950, p < 0.05). The duplicate use of ACE inhibitors in 5% of a population of community-dwelling elderly patients seems to be caused by both poor doctor-doctor communication and polypharmacy. This phenomenon could possibly be dangerous especially when potential additive adverse effects are taken into account.

AB - In this paper the data on the duplicate use of ACE inhibitors among a community-dwelling elderly population are presented. Using a questionnaire, 1000 subjects were interviewed concerning the use of drugs, 654 females, mean ± SD age: 72.6 ± 6.5 years. They were divided into two groups: Group A (5%) taking at least two ACE inhibitors (n = 50) and Group B: those who used either a single ACE inhibitor or no ACE inhibitor (n = 950). In Group A, 49 individuals were taking two different ACE inhibitors concomitantly and one was using three. The most commonly used ACE inhibitor was enalapril (29 of 50 subjects). Subjects in Group A consumed significantly more drugs, both of prescription (Rx) and nonprescription (OTC), compared to those in Group B (total means: 8.4 ± 2.8 vs. 6.7 ± 3.2; p < 0.01, Rx means: 6.3 ± 2.5 vs. 5.2 ± 2.8, p < 0.05, OTC means: 2.0 ± 1.6 vs. 1.6 ± 1.5, p < 0.05). Also, they were more likely to have consulted a cardiologist (17/50 vs. 201/950, p < 0.05). The duplicate use of ACE inhibitors in 5% of a population of community-dwelling elderly patients seems to be caused by both poor doctor-doctor communication and polypharmacy. This phenomenon could possibly be dangerous especially when potential additive adverse effects are taken into account.

KW - ACE inhibitors

KW - Duplicate use of antihypertensive drugs

KW - Inappropriateness of treatment

KW - Polypharmacy

UR - http://www.scopus.com/inward/record.url?scp=33847197949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847197949&partnerID=8YFLogxK

U2 - 10.1016/j.archger.2007.01.039

DO - 10.1016/j.archger.2007.01.039

M3 - Article

C2 - 17317465

AN - SCOPUS:33847197949

VL - 44

SP - 295

EP - 301

JO - Archives of Gerontology and Geriatrics

JF - Archives of Gerontology and Geriatrics

SN - 0167-4943

IS - SUPPL.

ER -